Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
SANTA CLARA, Calif., July 9, 2013
SANTA CLARA, Calif., July 9, 2013 /PRNewswire/ --NextBio, whose Big Data
technology enables users to apply genomic data from disparate sources in novel
and useful ways across life sciences research, today announced that Boehringer
Ingelheim has signed a multi-year renewal agreement to the NextBio Research
Platform. The new agreement also expands the user base for NextBio across
Boehringer Ingelheim's global research organization.
"Boehringer Ingelheim is one of the world's 20 leading pharmaceutical
companies and has been a user of NextBio Research for the past year," said
Saeid Akhtari, NextBio President and Chief Executive Officer. "This expanded
license and broadened access to the NextBio Research platform is a strong
endorsement of our technology's value for enabling life scientists to quickly
examine and understand their data in the context of published research
"NextBio Research provides a comprehensive platform for exploratory,
preclinical and early translational research in drug discovery and
biotechnology research," Mr. Akhtari added. "Integrating proprietary analysis
results with extensive curated content, NextBio enhances researchers' ability
to design experiments, test hypotheses and validate results, leading to better
target analysis, understanding of disease mechanisms, and analysis of results
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical
companies. Headquartered in Ingelheim, Germany, it operates globally with 140
affiliates and more than 46,000 employees. Since it was founded in 1885, the
family-owned company has been committed to researching, developing,
manufacturing and marketing novel medications of high therapeutic value for
human and veterinary medicine.
Social responsibility is a central element of Boehringer Ingelheim's culture.
Involvement in social projects, caring for employees and their families, and
providing equal opportunities for all employees form the foundation of the
global operations. Mutual cooperation and respect, as well as environmental
protection and sustainability are intrinsic factors in all of Boehringer
In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro.
R&D expenditure in the business area Prescription Medicines corresponds to
22.5% of its net sales.
NextBio provides a state of the art scientific platform to aggregate and
interpret large quantities of molecular and other life sciences data for
research and clinical applications. NextBio's platform integrates data from
multiple repositories and diverse technologies by means of a unique
correlation engine, which pre-computes billions of significant connections
between disparate public and proprietary clinical and experimental data. This
feature enables interpretation of an individual's molecular data. It also
provides translational researchers the ability to look across the clinical and
molecular data of entire populations for clinical trial stratification and
selection, hypotheses generation, and biomarker discovery. NextBio Clinical,
which recently passed an independent HIPAA audit, is designed for seamless
integration with existing clinical and research systems. Backed by highly
scalable, Big Data technology, it is capable of analyzing petabytes of data.
NextBio's platform is delivered as a SaaS (Software as a Service) solution
resulting in quick deployment and rapid return on investment.
Today, NextBio is used by researchers and clinicians in over 50 top commercial
and academic institutions including the National Institute of Health, The
University of Southern California, Sanford-Burnham Medical Research Institute,
Sanofi, Pfizer, Novartis, Celgene, Eli Lilly, Genzyme, Johnson & Johnson,
Merck, Regeneron, GlaxosmithKline, Harvard Medical School, Scripps Research
Institute, Stanford University, University of California at Berkeley, Takeda
and many others. To learn more about NextBio, please visit our website at
Contact: Saeid Akhtari, President and CEO, NextBio, email@example.com; Joan
Kureczka, Kureczka/Martin Associates, +1-415-821 2413, Mobile:
Press spacebar to pause and continue. Press esc to stop.